Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit

Qian Luo; Clese E Erikson

doi:10.1001/jama.2023.5038

Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient Limit

JAMA. 2023 May 23;329(20):1792-1794. doi: 10.1001/jama.2023.5038.

Authors

Qian Luo¹, Clese E Erikson¹

Affiliation

¹ Fitzhugh Mullan Institute for Health Workforce Equity, The George Washington University, Washington, DC.

No abstract available

Plain language summary

This study uses data from a Drug Enforcement Administration list of Drug Addiction Treatment Act (DATA)–waivered clinicians to examine trends in DATA-waivered clinicians’ active participation in prescribing buprenorphine overall and by patient limits between January 2017 and May 2021.

MeSH terms

Buprenorphine* / therapeutic use
Drug Prescriptions
Humans
Narcotic Antagonists / therapeutic use
Opiate Substitution Treatment / methods
Opioid-Related Disorders* / drug therapy
Practice Patterns, Physicians'* / legislation & jurisprudence
Prescriptions / statistics & numerical data
United States

Substances

Buprenorphine
Narcotic Antagonists